ACON Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

20.00K

+95.5%

-2.640

-99.81%

25.00K

+31.65%

-3.600

-99.78%

Estimates Revision

The market is revising No Change the revenue expectations for Aclarion, Inc. (ACON) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -8.31%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-8.31%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast ACON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACON is 23.00 USD with a low forecast of 23.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

23.00

Averages

23.00

High

23.00

Current: 0.000

Low

23.00

Averages

23.00

High

23.00

No data

Valuation Metrics

The current forward P/E ratio for Aclarion Inc (ACON.O) is -0.38, compared to its 5-year average forward P/E of -1.20. For a more detailed relative valuation and DCF analysis to assess Aclarion Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.20

Current PE

-0.38

Overvalued PE

-0.23

Undervalued PE

-2.17

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

27.70

Current PS

29.33

Overvalued PS

63.57

Undervalued PS

-8.17

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ACON News & Events

Events Timeline

No data

News

9.5

01-08NASDAQ.COM

PinnedAclarion (ACON) Shares Surge 50% Following 2025 Business Update and 2026 Outlook

7.5

01-08Benzinga

Aclarion Reports 69% Year-over-Year Scan Volume Growth Entering 2026 with Strong Financial Position

3.5

01-08NASDAQ.COM

Aclarion (ACON) Reports 69% Year-over-Year Growth in Nociscan Scan Volumes

People Also Watch

Frequently Asked Questions

What is Aclarion Inc (ACON) stock price today?

The current price of ACON is 8.17 USD — it has increased 42.09 % in the last trading day.

What is Aclarion Inc (ACON)'s business?

Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.

What is the price predicton of ACON Stock?

What is Aclarion Inc (ACON)'s revenue for the last quarter?

Aclarion Inc revenue for the last quarter amounts to 18.94K USD, increased 31.48 % YoY.

What is Aclarion Inc (ACON)'s earnings per share (EPS) for the last quarter?

Aclarion Inc. EPS for the last quarter amounts to -2.93 USD, decreased -99.78 % YoY.

What changes have occurred in the market's expectations for Aclarion Inc (ACON)'s fundamentals?

How many employees does Aclarion Inc (ACON). have?

Aclarion Inc (ACON) has 6 emplpoyees as of January 09 2026.

What is Aclarion Inc (ACON) market cap?

Today ACON has the market capitalization of 5.38M USD.